Clindamycin
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| |
| Clindamycin
| |
| Systematic (IUPAC) name | |
| (2S,4R)-N-((1R)-2-chloro- 1-((3R,4R,5S,6R)-3,4,5-trihydroxy- 6-(methylthio)-tetrahydro-2H-pyran-2-yl)propyl)- 1-methyl-4-propylpyrrolidine-2-carboxamide | |
| Identifiers | |
| CAS number | |
| ATC code | J01 G01AA10 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C18H33ClN2O5S |
| Mol. mass | 424.98 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 90% (oral) 4–5% (topical) |
| Protein binding | 90% |
| Metabolism | Hepatic |
| Half life | 2–3 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. | |
| Legal status | |
| Routes | Oral, topical, IV, intravaginal |
|
WikiDoc Resources for Clindamycin | |
|
Articles | |
|---|---|
|
Most recent articles on Clindamycin Most cited articles on Clindamycin | |
|
Media | |
|
Powerpoint slides on Clindamycin | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Clindamycin at Clinical Trials.gov Clinical Trials on Clindamycin at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Clindamycin
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Clindamycin Discussion groups on Clindamycin Patient Handouts on Clindamycin Directions to Hospitals Treating Clindamycin Risk calculators and risk factors for Clindamycin
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Clindamycin | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Clindamycin (rINN) (IPA: [klɪndəˈmaɪsən]) is a lincosamide antibiotic used in the treatment of infections caused by susceptible microorganisms. Clindamycin is a semisynthetic antibiotic derived from lincomycin by 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the lincomycin. Clindamycin is marketed under various trade names including Dalacin (Pfizer), Cleocin (Pfizer), and in a foam as Evoclin (Connetics) and Duac(Stiefel).
Indications
Clindamycin is used primarily to treat infections caused by susceptible anaerobic bacteria. Such infections might include infections of the respiratory tract, septicemia and peritonitis. In patients with hypersensitivity to penicillins, clindamycin may be used to treat infections caused by susceptible aerobic bacteria as well. It is also used to treat bone infections caused by Staphylococcus aureus. Topical application of clindamycin phosphate can be used to treat moderate to severe acne.
It is most effective against infections involving the following types of organisms:
- Aerobic gram-positive cocci, including some members of the Staphylococcus and Streptococcus (eg. pneumococcus) genera.
- Anaerobic gram-negative bacilli, including some members of the Bacteroides and Fusobacterium genera.
Clindamycin is also used occasionally in cases of suspected toxic shock syndrome in combination with a bactericidal agent such as vancomycin. The rationale for this approach is a presumed synergy between the bactericidal antibiotic, which causes the death of the bacteria by breakdown of the cell membrane, and clindamycin, which inhibits toxin synthesis.
Clindamycin has been proven to decrease the risk of preterm births in women diagnosed with bacterial vaginosis during early pregnancy to about a third of the risk of untreated women (Lamont, 2005).
Recently, clindamycin has been found to be useful in skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus (Daum, 2007).
Available forms
Clindamycin preparations for oral administration include capsules (containing clindamycin hydrochloride) and oral suspensions (containing clindamycin palmitate hydrochloride). It is also available for topical administration, in gel form and in a foam delivery system (both containing clindamycin phosphate), primarily as a prescription acne treatment.
Adverse effects
Common adverse drug reactions (ADRs) associated with clindamycin therapy—found in over 1% of patients—include: diarrhea, pseudomembranous colitis, nausea, vomiting, abdominal pain or cramps, rash, and/or itch. High intravenous doses may cause a metallic taste, and topical application may cause contact dermatitis (Rossi, 2006).
Pseudomembranous colitis is a potentially-lethal condition commonly associated with clindamycin, but which also occurs with other antibiotics. Overgrowth of Clostridium difficile, which is inherently resistant to clindamycin, results in the production of a toxin that causes a range of adverse effects, from diarrhea to colitis and toxic megacolon (Rossi, 2006).
Rarely—in less than 0.1% of patients—clindamycin therapy has been associated with anaphylaxis, blood dyscrasias, polyarthritis, jaundice, raised liver enzymes and/or hepatotoxicity (Rossi, 2006).
Pharmacology
Pharmacokinetics
Approximately 90% of an oral dose of clindamycin is absorbed from the gastrointestinal tract and it is widely distributed throughout the body, excluding the central nervous system. Adequate therapeutic concentrations can be achieved in bone. There is also active uptake into white blood cells, most importantly neutrophils. (Klempner and Styrt, 1981)
Clindamycin is extensively metabolised in the liver, with some metabolites being active, such as N-dimethyl clindamycin and clindamycin sulfoxide. The elimination half-life is 1.5 to 5 hours. Clindamycin is primarily eliminated by hepatic metabolism; after an intravenous dose of clindamycin phosphate, about 4.5% of the dose is excreted in urine as clindamycin and about 0.35% as the phosphate salt (Plaisance, 1989). The metabolites of clindamycin are excreted primarily in the urine (Klasco, 2006).
Mechanism of action
Clindamycin has a bacteriostatic effect. It interferes with bacterial protein synthesis, in a similar way to erythromycin and chloramphenicol, by binding to the 50S subunit of the bacterial ribosome. This causes antagonism if administered simultaneously and possible cross-resistance.
Veterinary use
In cats
Clindamycin has been used successfully in treating cats that are displaying symptoms of toxoplasmosis. This disease rarely causes symptoms in cats, but can do so in very young or immunocompromised kittens and cats. Toxoplasmosis is contagious to humans, and therefore cat owners, particularly pregnant women, should take precautions to prevent the spread of the disease.
References
- Daum RS (2007). "Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus". N Engl J Med 357 (4): 380–90. doi:10.1056/NEJMcp070747. PMID 17652653.
- Klasco RK, editor. Drugdex system, volume 128. Greenwood Village (CO): Thomson Micromedex; 2006.
- Klempner MS, Styrt B (1981). "Clindamycin uptake by human neutrophils". J. Infect. Dis. 144 (5): 472–9. PMID 6171600.
- Lamont RF (2005). "Can antibiotics prevent preterm birth--the pro and con debate". BJOG 112 Suppl 1: 67–73. doi:10.1111/j.1471-0528.2005.00589.x. PMID 15715599.
- Plaisance KI et al. (1989). "Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate". Antimicrob Agents Chemother 33 (5): 618–20. PMID 2751277. Full text at PMC: 172501.
- Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006.
Acne-treating agents (D10) | |
|---|---|
| Topical agents | Azelaic acid • Benzoyl peroxide • Glycolic acid • Light therapy • Salicylic acid • Tea tree oil |
| Antibiotics | Clindamycin • Erythromycin • Sulfacetamide • Tetracyclines • Trimethoprim |
| Hormonal | Antiandrogens • Contraceptives |
| Retinoids | Adapalene • Isotretinoin • Tazarotene • Tretinoin |
Gynecological anti-infectives and antiseptics (G01) | |
|---|---|
| Antibiotics | polyene antimycotic (Nystatin, Natamycin, Amphotericin B) - Candicidin - Chloramphenicol - Hachimycin - Oxytetracycline - Carfecillin - Mepartricin - Clindamycin - Pentamycin |
| Arsenic compounds | Acetarsol |
| Quinoline derivatives | Diiodohydroxyquinoline - Clioquinol - Chlorquinaldol - Dequalinium - Broxyquinoline - Oxyquinoline |
| Organic acids | Lactic acid - Acetic acid - Ascorbic acid |
| Sulfonamides | Sulfatolamide |
| Imidazole derivatives | Metronidazole - Clotrimazole - Miconazole - Econazole - Ornidazole - Isoconazole - Tioconazole - Ketoconazole - Fenticonazole - Azanidazole - Propenidazole - Butoconazole - Omoconazole - Oxiconazole - Flutrimazole |
| Triazole derivatives | Terconazole |
| Other | Clodantoin - Inosine - Policresulen - Nifuratel - Furazolidone - Methylrosaniline - Povidone-iodine - Ciclopirox - Protiofate - Lactobacillus fermentum - Copper usnate |
Antibacterials for systemic use: macrolides, lincosamides and streptogramins (J01F) | |
|---|---|
| Macrolides | Erythromycin - Spiramycin - Midecamycin - Oleandomycin - Roxithromycin - Josamycin - Troleandomycin - Clarithromycin - Azithromycin - Miocamycin - Rokitamycin - Dirithromycin - Flurithromycin - Telithromycin - Cethromycin |
| Lincosamides | Clindamycin - Lincomycin |
| Streptogramins | Pristinamycin - Quinupristin/dalfopristin |
de:Clindamycinfi:Klindamysiini th:คลินดามัยซิน
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
